Evidence map›Paper›PMID 37555194›Full record

ArticleJournal of kidney cancer and VHL2023

Hereditary Renal Cell Carcinoma: Is Age an Independent Criterion for Genetic Testing? A Large Cohort from a Latin America Referral Center.

Tomás Carminatti, Patricio Aitor García Marchiñena, Ignacio Pablo Tobia González, Valeria de Miguel, Marcelo Martín Serra, Pablo Germán Kalfayan, Alberto Manuel Jurado

Abstract read
In one paragraph

Article in Journal of kidney cancer and VHL, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tomás CarminattiUrology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Patricio Aitor García MarchiñenaUrology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Ignacio Pablo Tobia GonzálezUrology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Valeria de MiguelVHL unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Marcelo Martín SerraVHL unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Pablo Germán KalfayanVHL unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Alberto Manuel JuradoUrology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although age younger than 46 years has been an independent criterion for genetic testing in hereditary renal cell carcinoma (hRCC), there is a lack of evidence in the literature. This study aims to analyze whether a 46-year-old cut-off should be considered an independent genetic testing criterion and to elucidate risk factors predicting a positive genetic test. Observational study from January 2010 to December 2021. All patients under 46 years with a non-metastatic kidney mass and surgical indication were included. We assume patients who relapse in the first 5 years of follow-up could have a positive genetic test. As risk factors for relapse, ergo positive genetic test, we consider those patients who presented multifocal, bilateral, or previous renal tumor. Of 2,232 nephrectomies for kidney cancer, 301 patients met the inclusion criteria. The median follow-up was 60 months (IQR 29-101). The estimated five-year RFS was 94.4% (95% CI 91.3-97.5). Tumor size, previous renal tumor, multifocality, bilaterality, and pT3 or pT4 stage were independent recurrence risk factors. Genetic testing was performed on 24 patients. 10 patients had pathogenic variants in the test, 8 of which recurred during their life. 46-year-old cut-off has shown low performance in genetic testing. Therefore, we recommend that it be considered only if other hRCC risk criteria exist. Multifocality, bilaterality, and previous renal tumor could predict a positive genetic test.

Indexed as

Age criteria in Hereditary renal cell carcinomaearly-onset renal cell carcinomagenetic testingHereditary renal cell carcinomaVHL

Identifiers

PMID37555194
PMCPMC10404984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.